Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02680795
Title To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Belinostat

Age Groups: adult
Covered Countries USA


No variant requirements are available.